Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Repligen
AddedFeb 19, 2024
UpdatedJun 18, 2026
Repligen

Repligen

Public

Repligen Corporation: A global bioprocessing firm innovating in biologic drug manufacturing.

HQ
Waltham, MA, US
Founded
1981
Overview
Compare
Fundraising
Employees
Website

Repligen Corporation, founded in 1981 by Alexander Rich and Paul Schimmel, is a public bioprocessing company headquartered in Waltham, Massachusetts. The company's core mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide. Repligen focuses on developing, producing, and commercializing innovative products for manufacturing biologic drugs, serving life sciences companies, global biopharmaceutical firms, and contract manufacturers.

Notable figures associated with Repligen include its founders and key personnel like Tony J. The company is publicly traded on Nasdaq under the symbol RGEN and is a component of the S&P 400. Repligen has achieved significant milestones in bioprocessing innovation, simplifying complex workflows, and maximizing productivity. Its impact on the pharmaceutical industry is marked by its commitment to pushing the boundaries of what's possible in biologic drug manufacturing.

Repligen - Quick Facts

When was Repligen founded?

Repligen was founded in 1981.

Where is Repligen's headquarters located?

Repligen's headquarters is located in Waltham, MA, US.

When was Repligen's last funding round?

Repligen's most recent funding round was for $600M (USD) in December 2023.

How much has Repligen raised to-date?

As of Dec 6, 2023, Repligen has raised a total of $1.3B (USD).

How many employees does Repligen have?

Repligen has 2,000 employees as of Feb 6, 2024.

Repligen - Classification

Industry
  • Hardware
Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
  • Transactional
Customer
  • Enterprise
Main Product
  • Bioprocessing
  • Products
Tags
  • Life Sciences
Unique IDs
  • secCik: 0000730272
  • ticker: RGEN
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 2836Biological Products, Except Diagnostic Substances
  • 2800Chemicals And Allied Products
  • 2830Drugs
ISIC
  • 2100Manufacture of pharmaceuticals, medicinal chemical and botanical products
Show 22 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325414Biological Product (except Diagnostic) Manufacturing
  • 621000Ambulatory Health Care Services
  • 621500Medical and Diagnostic Laboratories
  • 621510Medical and Diagnostic Laboratories
  • 621511Medical Laboratories
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 8070Medical And Dental Laboratories
  • 8071Medical Laboratories
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research
ISIC
  • 8690Other human health activities